Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Marginal Zone Lymphoma

B-cell Lymphoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Rituximab

Complement System Proteins

Antineoplastic Agents, Immunological

Immunologic Factors

10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months

intralesional rituximab

patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum

supplemental autologous serum

Andrés JM Ferreri, MD

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

Preliminary data suggest intralesional rituximab is able to revert resistance to systemic rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of autologous serum seems to exhibit a synergistic effect on tumor regression. These two main aspects will be assessed in this trial.

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone

assessment of safety of intralesional rituximab in terms of incidence of \>/= G4 adverse events during the experimental treatment

assessment of activity of intralesional rituximab in terms of overall partial and complete response and duration of response

Andres J. M. Ferreri

Eye Diseases

Carcinoma

Carcinoma, Squamous Cell

Conjunctival Neoplasms

Eye Neoplasms

Conjunctival Diseases

Coagulants

Mitomycins

Mitomycin

Fibrin Tissue Adhesive

Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.

Treatment of diffuse ocular surface squamous neoplasia

A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.

Surgical excision of the conjunctival tumour . A superficial corneal scraping was performed for corneal lesion then double freeze-thaw cryotherapy was applied to limbal edge and conjunctival margins.The amniotic membrane graft was secure and attached to the sclera and conjunctiva using ﬁbrin glue.Topical mitomycin C 0.04%eye drop was prescribed 4 times daily per treatment cycle (1 cycle=1 week on 1 week off).

AS-OCT Guided Treatment of Diffuse CSCC

Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Conjunctival Squamous Cell Carcinoma (CSCC) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)

Any recurrence which is detected clinically or/and by AS-OCT

Benha University

lecturer of ophthalmology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma	NCT01514344	Ocular Adnexal ...	intralesional r... supplemental au...	18 Years -	IRCCS San Raffaele
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma	NCT01514344	Ocular Adnexal ...	intralesional r... supplemental au...	18 Years -	IRCCS San Raffaele
AS-OCT Guided Treatment of Diffuse CSCC	NCT03515954	Conjunctival Ne...	Treatment of di...	18 Years -	Benha University
AS-OCT Guided Treatment of Diffuse CSCC	NCT03515954	Conjunctival Ne...	Treatment of di...	18 Years -	Benha University

Spots Global Cancer Trial Database for conjunctiva

Every month we try and update this database with for conjunctiva cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for conjunctiva

Every month we try and update this database with for conjunctiva cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for conjunctiva cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.